InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $6.5M Registered Direct Offering

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced its entry into a definitive agreement with a single health care-focused U.S. institutional investor, for the purchase and sale of 6,132,076 shares of the company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 6,132,076 shares of common stock at a purchase price per share (and accompanying warrant) of $1.06 in a registered direct offering. According to the update, the warrants will have an exercise price of $1.06 per share, will be initially exercisable beginning six months following the date of issuance and will expire five years from the initial exercise date. Subject to the satisfaction of customary conditions, the closing of the offering is expected to occur on or about July 20, 2022. The gross proceeds from the offering are expected to be approximately $6.5 million. 180 Life Sciences intends to use the net proceeds for research and development expenses and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

To view the full press release, visit https://ibn.fm/CRPDA

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company. The company is driving groundbreaking studies into clinical programs, which are seeking to develop treatments for major unmet clinical needs. The company’s primary platform is a novel program to treat inflammatory disorders using anti-TNF (tumor necrosis factor). For more information, visit the company’s website at www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.